Marshall Wace
ESPR

Marshall Wace’s Esperion Therapeutics ESPR Stock Holding History

Marshall Wace’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-300,000
Closed -$10.1M – 1666
2020
Q2 		$10.1M Buy
+300,000
New +$12.6M 0.07% 281

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Marshall Wace's ESPR Position: Q2 2026 in Review

Marshall Wace reduced its Esperion Therapeutics (ESPR) stake by 100% in Q2 2026, selling an estimated $19.8M and leaving 14,118 shares worth $44.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2996.

Marshall Wace first reported a position in ESPR in Q4 2014 and has held it in 27 quarters since. The position peaked at $66.2M in Q2 2020. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Marshall Wace held 14,118 shares of Esperion Therapeutics worth $44.6K as of Q2 2026.
  • Marshall Wace sold 7,060,965 Esperion Therapeutics shares in Q2 2026, an estimated $19.8M.
  • Esperion Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2996 holding.
  • Marshall Wace first reported a position in Esperion Therapeutics in Q4 2014 and has held it in 27 quarters since.
  • Marshall Wace's Esperion Therapeutics position peaked at $66.2M in Q2 2020.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.